New hope for kids with arthritis: Long-Term drug study launches
NCT ID NCT07553182
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing the long-term safety and effectiveness of the drug filgotinib in children and adolescents aged 8 to 17 with juvenile idiopathic arthritis. Participants must have already completed a previous filgotinib study and shown improvement. The goal is to see if the drug remains safe and helps control arthritis symptoms over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
filgotinib
What this could lead to
If successful, this could confirm filgotinib as a safe long-term treatment option for children and teens with juvenile idiopathic arthritis.
What could go wrong
This is an open-label extension study, so there is no placebo group for comparison. Long-term side effects are still being monitored, and the results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS (JIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asklepios Klinik Sankt Augustin GmbH
NOT_YET_RECRUITINGSankt Augustin, 53757, Germany
Contact
-
Bicetre Hospital
NOT_YET_RECRUITINGLe Kremlin-Bicêtre, 94270, France
Contact
-
Great Ormond Street Hospital for Children
NOT_YET_RECRUITINGLondon, WC1N 3JH, United Kingdom
Contact
-
Hamburger Zentrum für Kinder- und Jugendrheumatologie
RECRUITINGHamburg, 22081, Germany
Contact